The Primatene Mist inhaler is the only over-the-counter (OTC) asthma inhaler approved by the FDA for the relief of asthma ...

If currently taking a prescription monoamine oxidase inhibitor (MAOI) (eg, certain drugs taken for depression, psychiatric or emotional conditions, or Parkinson’s disease), or for 2 weeks after ...

Amphastar's Q2 2024 revenue grew 25% year-over-year to $182.4 million, primarily driven by BAQSIMI and Primatene MIST sales. Primatene MIST faces future challenges as its key patent expires in ...

However, now that a topical gel for ED, Eroxon, is available over-the-counter without a prescription, a big question is whether discussions about ED will become more, well, topical, natural and ...

Over-the-counter, or OTC, markets are decentralized financial markets that give investors access to smaller, unlisted companies, foreign currencies, derivatives and other securities. Many ...

A key highlight for the quarter was Primatene MIST which achieved its highest quarterly sales since the launch reaching $26 million in sales. This performance is a significant step toward our goal ...

In July 2023, the FDA approved Opill—a progestin-only birth control pill—for over-the-counter sale, making it the first oral contraceptive available without a prescription. It is expected to ...

It was only two years ago that hearing aids became available over the counter in the US, but the positive impact of these devices is long-standing. And they've proven themselves as great tools for ...

The Finished Pharmaceutical Products segment manufactures, markets, and distributes Primatene Mist, enoxaparin, naloxone, phytonadione, lidocaine, and other critical and non-critical care drugs.

Our strategic initiatives regarding our regulatory filings and commercial portfolio execution remain on track and we are well positioned to continue the growth of our key revenue drivers with BAQSIMI, ...